Suppr超能文献

Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.

作者信息

Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K, Hasegawa Y

机构信息

Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital.

出版信息

Jpn J Cancer Res. 1999 Feb;90(2):249-53. doi: 10.1111/j.1349-7006.1999.tb00740.x.

Abstract

Prognostic factors which can forecast short-term survival in patients with stage IV non-small cell lung cancer have not been well evaluated. Characteristics of such factors may be different from those for overall survival, and would be an important eligibility criterion for clinical trials of chemotherapy. We retrospectively analyzed the data of 158 patients with stage IV non-small cell lung cancer whose performance status was 0, 1 or 2. Univariate and multivariate logistic regression models revealed demographic variables which significantly correlated with the survival at 8 or 12 weeks. The univariate model showed the following significant variables: T factor, N factor, number of organs with metastases, grade of performance status, weight loss within 6 months, evidence of metastasis either at bone or lymph node, and lactate dehydrogenase level. The subsequent multivariate model demonstrated that both grade of performance status under 2 and number of metastasized organs less than 3 are important factors for 8- or 12-week survival. The survival rate in patients meeting the two criteria (grade of performance status under 2 and number of metastasized organs less than 3) and in those meeting only one of them was 93% versus 80% at 8 weeks (P = 0.030) and 88% versus 62% at 12 weeks (P < 0.001), respectively. Grade of performance status and number of organs with metastases appear to be important prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.

摘要

相似文献

1
Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer.
Jpn J Cancer Res. 1999 Feb;90(2):249-53. doi: 10.1111/j.1349-7006.1999.tb00740.x.
4
[Prognostic factors in unresectable lung cancer].
Gan To Kagaku Ryoho. 1988 Jul;15(7):2035-42.
5
7
[Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Dtsch Med Wochenschr. 2006 Nov 24;131(47):2643-8. doi: 10.1055/s-2006-956268.
8
Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.
World J Surg Oncol. 2016 Nov 25;14(1):295. doi: 10.1186/s12957-016-1048-5.

引用本文的文献

1
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).
Int J Oncol. 2016 Jan;48(1):13-27. doi: 10.3892/ijo.2015.3219. Epub 2015 Oct 29.
2
Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.
Invest New Drugs. 2012 Aug;30(4):1628-40. doi: 10.1007/s10637-011-9714-5. Epub 2011 Jul 8.
3
Predictors of survival in patients with bone metastasis of lung cancer.
Clin Orthop Relat Res. 2008 Mar;466(3):729-36. doi: 10.1007/s11999-007-0051-0. Epub 2008 Jan 3.

本文引用的文献

1
Revisions in the International System for Staging Lung Cancer.
Chest. 1997 Jun;111(6):1710-7. doi: 10.1378/chest.111.6.1710.
2
Treatment of advanced non-small cell lung cancer.
Semin Oncol. 1994 Aug;21(4 Suppl 7):7-18.
5
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
J Clin Oncol. 1986 Jan;4(1):14-22. doi: 10.1200/JCO.1986.4.1.14.
7
Prognostic uncertainty in terminal care: can the Karnofsky index help?
Lancet. 1985 May 25;1(8439):1204-6. doi: 10.1016/s0140-6736(85)92876-4.
10
Chemotherapy of lung cancer.
N Engl J Med. 1992 Nov 12;327(20):1434-41. doi: 10.1056/NEJM199211123272006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验